Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

300.83
-7.1700-2.33%
Post-market: 297.00-3.8300-1.27%17:34 EDT
Volume:954.85K
Turnover:289.02M
Market Cap:39.22B
PE:-143.37
High:310.22
Open:309.00
Low:300.27
Close:308.00
Loading ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision

Simply Wall St.
·
24 Mar

Alnylam price target raised to $338 from $300 at Scotiabank

TipRanks
·
22 Mar

Alnylam Pharma Stock (ALNY) Rockets on FDA Drug Approval

TIPRANKS
·
22 Mar

Alnylam Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
22 Mar

Alnylam Stock Jumps After the FDA Approves Its Heart Drug -- WSJ

Dow Jones
·
22 Mar

Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy

Zacks
·
22 Mar

BUZZ-U.S. STOCKS ON THE MOVE-ACNB, Carnival Corp, Boeing

Reuters
·
21 Mar

BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue?

Zacks
·
21 Mar

Alnylam Pharmaceuticals Shares up 4% After FDA Expands Approval for Drug to Treat Rare Heart Disease

THOMSON REUTERS
·
21 Mar

Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
21 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Microchip Technology, IAC, Micron Technology

Reuters
·
21 Mar

Sector Update: Health Care Stocks Steady Premarket Friday

MT Newswires Live
·
21 Mar

RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating

MT Newswires Live
·
21 Mar

Alnylam Pharma (ALNY) Initiated with a Hold at Cantor Fitzgerald

TIPRANKS
·
21 Mar

Alnylam Pharma (ALNY) Gets a Buy from Chardan Capital

TIPRANKS
·
21 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Cowell, Nike, Alnylam Pharma

Reuters
·
21 Mar

Alnylam's Amvuttra Seen as Mega Blockbuster -- Market Talk

Dow Jones
·
21 Mar

Alnylam shares rise on expanded heart drug approval

Reuters
·
21 Mar

Alnylam Pharmaceuticals Inc : Wells Fargo Raises Target Price to $287 From $275

THOMSON REUTERS
·
21 Mar

Alnylam Pharmaceuticals Price Target Maintained With a $320.00/Share by Needham

Dow Jones
·
21 Mar